- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01112085
MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) (MINIMA-2)
Phase 2 Study of Microdoses of Ranibizumab in Diabetic Macular Edema - the MINIMA 2 Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The MINIMA-2 Study is a multi-center clinical trial that initiated in order to investigate the effect of microdoses of ranibizumab in diabetic macular edema. The duration of the study is up to 13 months. Patients with diabetic macular edema will be randomized into 2 different groups. Consented subjects will receive monthly injections over a 6-month treatment period, and a 6 month follow-up and treatment period. Several eye examinations and procedures will be performed to evaluate response to the treatment. These include best corrected visual acuity testing (ETDRS), contrast sensitivity testing, ophthalmic examination, fluorescein angiography (FA)and macular thickness measurements based on optical coherence tomography (OCT). Serum chemistry, hematology and glycosylated hemoglobin HbA1c testing, urinalysis and pregnancy testing will be performed at screening visit (Days -14 to 0) and two more times during the study.
Approximately 72 patients with a baseline central foveal thickness by OCT of at least 270 will be included. The BCVA must be worst than 20/40 but better than or equal to 20/320 due diabetic macular edema.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Córdoba, Argentina
- Centro Privado de Ojos Rogamosa SA y Fundación VER
-
-
-
-
-
San Luis Potosí, Mexico, 78250
- Hospital Central
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44600
- Hospital San José
-
Zapopan, Jalisco, Mexico, 44116
- Centro de Retina Médica y Quirúrgica S. C.
-
Zapopan, Jalisco, Mexico, 45100
- Hospital Regional Valentín Gómez Farías
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- Hospital Universitario Doctor José Eleuterio Gonzalez
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, 18 years of age or older
- Subjects with diagnosis of diabetes mellitus (Type I or II)
- Signed informed consent
- Patient must be able to comply with study assessments
- Clinical sings and angiographic evidence of diabetic macular edema
- Central foveal thickness of at least 270 assessed by OCT
- Best corrected visual acuity of 20/40 to 20/320 (ETDRS chart) in the study eye
Exclusion Criteria:
- Patients who do not fulfill the inclusion criteria
- Use of any intraocular or periocular drug injection over the previous 3 months
- Macular or panretinal photocoagulation within 3 months of the study entry in the study eye
- High myopia (more than 6D)
- Any ocular disorders in the study eye that may confound interpretation of study results including patients with choroidal neovascularization, macular hole, retinal detachment, epiretinal membrane, ischemic maculopathy or any other retinal vascular disease such as vascular occlusive diseases.
- Vitreomacular traction
- Subretinal fibrosis
- Uncontrolled or advanced glaucoma
- Active ocular inflammation or history of active intraocular inflammation during the 6 months prior to enrollment of the study
- Any ophthalmic surgery performed within 3 months prior to study entry in the study eye
- Previous pars plana vitrectomy in the study eye
- History of ocular trauma of any type in the study eye
- Subjects with media opacities or abnormalities that would preclude observation of the retina in the study eye, per the investigator's judgement
- History of fluorescein allergy
- Known hypersensitivity to ranibizumab
- History of stroke or Myocardial infraction within 6 months
- Pregnancy, lactation or any women with no adequate contraception
- Participation in another simultaneous medical investigation or trial
- Any other condition that, in the opinion of the investigator, would produce a significant hazard or jeopardize the safety of the patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranibizumab 0.05mg
Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
|
Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
|
Experimental: Ranibizumab 0.5mg
Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
|
Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best corrected visual acuity
Time Frame: 12 months
|
Improvement in vision of best corrected visual acuity of 15 or more letters, or a final vision of 20/25 (50 letters) or better if best corrected visual acuity (BCVA) was 20/40 (40 letters)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in central retinal thickness and volume by OCT
Time Frame: 6 months and 12 months
|
Changes in central retinal thickness and volume assessed by optical coherence tomography (OCT)
|
6 months and 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Arturo Santos, MD PhD, Centro de Retina Médica y Quirúrgica S. C.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MINIMA-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Ranibizumab 0.05mg
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Aileron Therapeutics, Inc.Completed
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted